Ten Analysts Act on Boston Scientific; Jefferies Downgrades to Hold

Ten firms acted on Boston Scientific (NYSE: BSX) on Thursday, with Jefferies downgrading the stock to hold from buy and nine cutting price targets.

Before the open, BTIG cut its target to $49 from $56 and kept its buy rating, while Baird kept its outperform rating and raised its target to $51 from $50. During the session, Wells Fargo cut its target to $45 from $48 with an equal-weight rating, UBS cut its target to $57 from $67 at buy, Leerink Partners cut its target to $50 from $55 at outperform, Citigroup cut its target to $44 from $48 at neutral, and RBC Capital cut its target to $52 from $70 at outperform. After the close, Bernstein cut its target to $49 from $54 at outperform, Canaccord Genuity cut its target to $48 from $66 at buy, and Jefferies moved to hold from buy with a target of $46, down from $60.

Stock and coverage

The stock closed at $42.69 on Thursday, up 0.6%, while the S&P 500 ETF fell 0.4% in the session. Shares had closed at $42.43 on Wednesday, Oct. 28, and were down 2.8% over the 20 sessions to that close.

Of the 24 firms that rated Boston Scientific in the past year, 19 rated it positive and five neutral before Thursday's actions, with none negative. The median target among those firms was $66.50, against a low of $48 and a high of $118.

Company scale

For scale, Boston Scientific reported revenue of $20.07 billion for 2025, up 20% from a year earlier, and net income to common shareholders of $2.90 billion, up 56%.

The actions came the day after the company filed a Form 8-K with the SEC on Oct. 28.